Inventiva announces the randomization of the first patient in China in the global Phase III NATiV3 clinical study, and estimates that the first visit of the last patient in this study is now expected in the first quarter of 2024.

This randomization triggers a $3 million milestone payment from CTTQ, by which Inventiva is expected to have met the conditions precedent necessary to draw down the second €25 million tranche of the EIB loan.

NATiV3 is a long-term study of lanifibranor in adults with biopsy-proven non-cirrhotic NASH and stage F2/F3 liver fibrosis. The study is taking place in 24 countries and is expected to enroll around 900 patients.

Copyright (c) 2023 CercleFinance.com. All rights reserved.